WEBSITE BSE:544703 NSE: DSFCL Inc. Year: 2021 Industry: Chemicals My Bucket: Add Stock
Last updated: 15:41
No Notes Added Yet
1. Business Overview
DCM Shriram Fine Chemicals Ltd. (DSFCL) is a subsidiary of DCM Shriram Ltd., focused on the manufacturing and sale of fine and specialty chemicals. The company's core business involves producing complex, high-purity chemical compounds that serve as intermediates or active ingredients for various industrial applications. DSFCL caters primarily to Business-to-Business (B2B) customers in sectors such as pharmaceuticals, agrochemicals, polymers, and water treatment. Its business model relies on developing specific chemical solutions and supplying them to clients who integrate these products into their final goods, generating revenue through the sale of these specialized chemical products.
2. Key Segments / Revenue Mix
DSFCL's operations are typically segmented by the types of fine and specialty chemicals produced and their primary end-user applications. While specific revenue contributions are not publicly detailed for this subsidiary, its portfolio would generally include:
Pharmaceutical Intermediates: Chemicals crucial for the synthesis of Active Pharmaceutical Ingredients (APIs).
Agrochemical Intermediates: Raw materials used in the production of crop protection chemicals (pesticides, herbicides).
Specialty Polymers & Additives: Chemicals that modify or enhance the properties of plastics and other materials.
Other Industrial Specialty Chemicals: Products for niche applications in industries like water treatment, textiles, and personal care.
The revenue mix would largely depend on the demand cycles and growth trajectory of these key consuming industries.
3. Industry & Positioning
DSFCL operates within the Indian Fine and Specialty Chemicals industry, a sub-sector of the broader Chemicals industry. This segment is characterized by higher value addition, sophisticated manufacturing processes, and often requires specialized technical expertise and adherence to stringent quality and regulatory standards. The Indian fine chemicals market is experiencing significant growth, driven by rising domestic consumption, particularly from the pharmaceutical and agrochemical sectors, and global supply chain re-alignment efforts (e.g., "China Plus One" strategy). As a subsidiary of the well-established DCM Shriram Group, DSFCL benefits from strong parental backing, potential access to backward integration (e.g., basic chemicals from other group units), and established corporate governance, positioning it to compete with both domestic and international specialty chemical manufacturers based on product quality, technical capabilities, and supply reliability.
4. Competitive Advantage (Moat)
DSFCL's competitive advantages are likely derived from:
Process Expertise & R&D: Proprietary know-how in complex chemical synthesis and process optimization, supported by research and development capabilities to innovate and develop new high-value molecules.
Customer Lock-in / Switching Costs: For specialty chemicals, customers often qualify specific suppliers due to rigorous quality and application requirements, leading to high switching costs once a product is integrated into their production.
Backward Integration & Synergies: As part of DCM Shriram Ltd., it may leverage group-level integration, potentially accessing key raw materials or shared infrastructure, which can result in cost efficiencies and supply chain stability.
Regulatory & Quality Compliance: Adherence to strict quality control standards and regulatory requirements (e.g., cGMP for pharmaceutical intermediates) acts as a barrier to entry for less compliant competitors.
5. Growth Drivers
Robust End-User Industry Demand: Continued expansion of the Indian pharmaceutical and agrochemical sectors, driving increased demand for intermediates and specialty chemicals.
"China Plus One" Strategy: Global manufacturers diversifying their chemical sourcing away from China, creating significant export opportunities for Indian specialty chemical producers.
Import Substitution: Government focus and industry efforts to enhance domestic manufacturing capabilities and reduce reliance on chemical imports.
Capacity Expansion & New Product Development: Strategic investments in increasing production capacities and introducing new, higher-value-added products through sustained R&D efforts.
Technological Advancement: Adoption of efficient and environmentally friendly production processes to enhance competitiveness and comply with evolving standards.
6. Risks
Raw Material Price Volatility: Significant fluctuations in the prices of key feedstocks and intermediates can directly impact production costs and profitability.
Intense Competition: The specialty chemicals market is highly competitive, with numerous domestic and international players, which can lead to pricing pressures and margin erosion.
Regulatory and Environmental Changes: Stringent and evolving environmental regulations, safety standards, and intellectual property rights enforcement can increase operational costs and compliance burdens.
Economic Slowdown: A downturn in global or domestic economies could reduce demand from key end-user industries, affecting sales volumes and revenue.
Foreign Exchange Fluctuations: As the company may engage in import of raw materials or export of finished goods, currency volatility can adversely affect financial performance.
7. Management & Ownership
DCM Shriram Fine Chemicals Ltd. is a subsidiary of DCM Shriram Ltd., an established Indian conglomerate. This implies that the company benefits from the strategic direction, financial support, and strong governance framework of its parent. The management team is expected to operate under the professional and experienced leadership common within the broader DCM Shriram Group, which has a long history of industrial operations and a diversified portfolio.
8. Outlook
DSFCL's outlook appears generally favorable, underpinned by strong growth tailwinds in its key end-user industries, particularly pharmaceuticals and agrochemicals, both domestically and internationally. The global "China Plus One" strategy presents a notable structural opportunity for increased exports. However, the company operates in an industry susceptible to raw material price volatility, intense competition, and evolving regulatory landscapes. Its ability to strategically expand capacity, continuously innovate, and effectively manage operational efficiencies and supply chain risks will be critical for sustained growth and profitability. The robust backing and strategic oversight from the DCM Shriram Group provide a stable foundation for navigating these industry dynamics.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹234 Cr.
Stock P/E 12.2
P/B 1.1
Current Price ₹26.9
Book Value ₹ 24.5
Face Value 2
52W High ₹52.5
Dividend Yield 0%
52W Low ₹ 17.3
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2024 | Dec 2025 |
|---|---|---|
| Net Sales | 93 | 97 |
| Other Income | 1 | 1 |
| Total Income | 94 | 98 |
| Total Expenditure | 88 | 97 |
| Operating Profit | 6 | 1 |
| Interest | 0 | 0 |
| Depreciation | 2 | 2 |
| Exceptional Income / Expenses | 0 | 0 |
| Profit Before Tax | 3 | -1 |
| Provision for Tax | 1 | 0 |
| Profit After Tax | 2 | -1 |
| Adjustments | 0 | 0 |
| Profit After Adjustments | 2 | -1 |
| Adjusted Earnings Per Share | 0.3 | -0.2 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Net Sales | 413 | 429 | 190 |
| Other Income | 4 | 4 | 2 |
| Total Income | 417 | 433 | 192 |
| Total Expenditure | 372 | 397 | 185 |
| Operating Profit | 44 | 36 | 7 |
| Interest | 2 | 2 | 0 |
| Depreciation | 9 | 9 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 |
| Profit Before Tax | 33 | 26 | 2 |
| Provision for Tax | 9 | 7 | 1 |
| Profit After Tax | 24 | 19 | 1 |
| Adjustments | 0 | 0 | 0 |
| Profit After Adjustments | 24 | 19 | 1 |
| Adjusted Earnings Per Share | 2.8 | 2.2 | 0.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 4% | 0% | 0% | 0% |
| Operating Profit CAGR | -18% | 0% | 0% | 0% |
| PAT CAGR | -21% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 9% | 11% | 11% | 11% |
| ROCE Average | 12% | 14% | 14% | 14% |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Shareholder's Funds | 202 | 215 |
| Minority's Interest | 0 | 0 |
| Borrowings | 8 | 3 |
| Other Non-Current Liabilities | 17 | 17 |
| Total Current Liabilities | 69 | 74 |
| Total Liabilities | 296 | 308 |
| Fixed Assets | 136 | 130 |
| Other Non-Current Assets | 5 | 5 |
| Total Current Assets | 154 | 173 |
| Total Assets | 296 | 308 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 0 |
| Cash Flow from Operating Activities | 28 | 14 |
| Cash Flow from Investing Activities | -18 | 0 |
| Cash Flow from Financing Activities | -15 | -15 |
| Net Cash Inflow / Outflow | -4 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 |
| # | Mar 2024 | Mar 2025 |
|---|---|---|
| Earnings Per Share (Rs) | 2.77 | 2.21 |
| CEPS(Rs) | 3.79 | 3.22 |
| DPS(Rs) | 0.75 | 0.67 |
| Book NAV/Share(Rs) | 23.2 | 24.71 |
| Core EBITDA Margin(%) | 9.77 | 7.53 |
| EBIT Margin(%) | 8.53 | 6.39 |
| Pre Tax Margin(%) | 7.97 | 5.99 |
| PAT Margin (%) | 5.8 | 4.43 |
| Cash Profit Margin (%) | 7.93 | 6.46 |
| ROA(%) | 8.17 | 6.35 |
| ROE(%) | 11.96 | 9.21 |
| ROCE(%) | 16.28 | 12.48 |
| Receivable days | 63.45 | 65.34 |
| Inventory Days | 38.59 | 39.78 |
| Payable days | 70.18 | 72.64 |
| PER(x) | 0 | 0 |
| Price/Book(x) | 0 | 0 |
| Dividend Yield(%) | 0 | 0 |
| EV/Net Sales(x) | 0.08 | 0.06 |
| EV/Core EBITDA(x) | 0.75 | 0.76 |
| Net Sales Growth(%) | 0 | 4 |
| EBIT Growth(%) | 0 | -22 |
| PAT Growth(%) | 0 | -20.51 |
| EPS Growth(%) | 0 | -20.51 |
| Debt/Equity(x) | 0.08 | 0.05 |
| Current Ratio(x) | 2.24 | 2.34 |
| Quick Ratio(x) | 1.6 | 1.66 |
| Interest Cover(x) | 15.22 | 15.68 |
| Total Debt/Mcap(x) | 0 | 0 |
| # | Dec 2025 | Mar 2026 |
|---|---|---|
| Promoter | 50.11 | 50.11 |
| FII | 1.49 | 1.48 |
| DII | 8.97 | 8.27 |
| Public | 39.43 | 40.14 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Dec 2025 | Mar 2026 |
|---|---|---|
| Promoter | 4.36 | 4.36 |
| FII | 0.13 | 0.13 |
| DII | 0.78 | 0.72 |
| Public | 3.43 | 3.49 |
| Others | 0 | 0 |
| Total | 8.7 | 8.7 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.